Daniel Katz is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 22 Apr 2024.
Clinical trials
- Virtual Reality for Pain Control in US-Guided Obstetric Needle Procedures
Sponsor: Icahn School of Medicine at Mount Sinai
- Auricular Neuromodulation for FESS
Sponsor: Icahn School of Medicine at Mount Sinai
- Intrathecal Dexmedetomidine vs Epinephrine
Sponsor: Icahn School of Medicine at Mount Sinai
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CVRx, Inc.Program year20251 payment
- CVRx, Inc.Program year20243 payments
- CVRx, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
60.4%Statin14.4%Rosuvastatin Calcium71%Atorvastatin Calcium29%Part D<11 patientsAldosterone antagonist (MRA)13.6%Spironolactone60%Eplerenone40%Part D<11 patients+ 5 more classes in this area
Cancer & immunology
14.4%Calcineurin inhibitor7.7%Tacrolimus58%Envarsus Xr42%Part D<11 patientsKinase inhibitor6.7%Sirolimus100%Part D<11 patientsMetabolism & gastrointestinal
8.2%SGLT2 inhibitor8.2%Jardiance64%Farxiga36%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Identifying Proteomic Markers of Exercise Training in Heart Failure
Stanford University
FY2026$194,076K23HL164980 - Identifying Proteomic Markers of Exercise Training in Heart Failure
Stanford University
FY2025$193,260K23HL164980 - Identifying Proteomic Markers of Exercise Training in Heart Failure
Stanford University
FY2024$193,260K23HL164980
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”